Financial reports
ARS
2023 FY
Annual report to shareholders
24 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
20 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Regulation FD Disclosure
11 Mar 24
8-K
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
29 Feb 24
8-K
Regulation FD Disclosure
26 Feb 24
8-K
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
14 Nov 23
8-K
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
6 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
8-K
Regulation FD Disclosure
11 Sep 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
8-K
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
10 Aug 23
8-K
Entry into a Material Definitive Agreement
29 Jun 23
Registration and prospectus
S-3
Shelf registration
31 Aug 23
424B5
Prospectus supplement for primary offering
29 Jun 23
424B3
Prospectus supplement
27 Jun 23
424B5
Prospectus supplement for primary offering
26 Jun 23
424B5
Prospectus supplement for primary offering
11 May 23
S-3
Shelf registration
1 May 23
POS AM
Prospectus update (post-effective amendment)
1 May 23
424B3
Prospectus supplement
28 Mar 23
POS AM
Prospectus update (post-effective amendment)
20 Mar 23
424B3
Prospectus supplement
14 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Mar 22
DEFA14A
Additional proxy soliciting materials
24 Mar 22
DEFR14A
Revised proxy
4 Mar 22
DEFA14A
Additional proxy soliciting materials
25 Feb 22
DEFM14A
Proxy related to merger
14 Feb 22
PRER14A
Preliminary revised proxy
11 Feb 22
Other
EFFECT
Notice of effectiveness
12 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
EFFECT
Notice of effectiveness
10 May 23
EFFECT
Notice of effectiveness
5 May 23
CORRESP
Correspondence with SEC
5 May 23
UPLOAD
Letter from SEC
4 May 23
EFFECT
Notice of effectiveness
28 Mar 23
EFFECT
Notice of effectiveness
3 Aug 22
CORRESP
Correspondence with SEC
29 Jul 22
Ownership
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
5 Mar 24
4
da Silva Jorge Santos
29 Feb 24
4
Kristian Reich
29 Feb 24
4
da Silva Jorge Santos
23 Feb 24
4
Kristian Reich
22 Feb 24
4
da Silva Jorge Santos
20 Feb 24
4
Kristian Reich
16 Feb 24
144
Notice of proposed sale of securities
15 Feb 24
SC 13G/A
Merck Healthcare KGaA
15 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24